Clinical trials: Malignant Ascites
Brenner Tumor, Malignant Ascites
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02122185
- Testing
- metformin hydrochloride, Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Chicago
Gynecologic Cancer, Gastrointestinal Cancer
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.
- Trial name
- NCT03367247
- Testing
- BOLSTER, Enhanced Discharge Planning (EDP)
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Dana-Farber Cancer Institute
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Malignant Ascites
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
- Trial name
- NCT00326885
- Testing
- catumaxomab
- Where
- 18 sites in United States
- Volunteers
- 32 people
- Sponsor
- Neovii Biotech
Peritoneal Neoplasms, Ascites
Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
This trial studies efficacy and safety of combination of modulated electro-hyperthermia (mEHT) with Traditional Chinese Medicine (TCM) in treatment of peritoneal carcinomatosis with malignant ascites versus standard chemoinfusion…
- Conditions
- Peritoneal Neoplasms, Ascites, Yang Deficiency, Yin Deficiency
- Trial name
- OTMA-RII (NCT02638051)
- Testing
- Modulated Electro-Hyperthermia (mEHT), TCM Herbal Decoction (Shi Pi), IPCI (CDDP+5FU)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Galenic Research Institute Ltd
Ovarian Cancer, Ovarian Neoplasms
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
Background: Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ascites, Gastrointestinal Cancer
- Trial name
- NCT02417753
- Testing
- AZD9150
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Ascites
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites
The purpose of this study is to assess in a controlled prospective setting, the safety of the use of Pleurx catheters and standard therapeutic paracentesis in patients with malignant ascites.
- Trial name
- NCT01077063
- Testing
- paracentesis, Pleurx catheter
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi